US Patent 9,320,740: Claim Scope, Zerbaxa Coverage and Patent Landscape

US Patent 9,320,740 protects sterile ceftolozane-tazobactam products manufactured and packaged as separate components in a sealed unit-dose container, principally at the marketed 2:1 active-ingredient ratio. The patent reaches the commercial Zerbaxa presentation, including the 1,000 mg/500 mg vial, individually lyophilized components, aseptic filling, inert-gas blanketing, reconstitution capability and intravenous administration. Its strongest commercial value is formulation and packaging protection rather than protection of either active ingredient alone.

What does US Patent 9,320,740 protect?

The patent contains two principal independent claim structures:

Claim group	Core subject matter	Principal limitations
Claims 1-9	Sterile pharmaceutical composition	Ceftolozane plus tazobactam, 2:1 active-weight ratio, sealed unit-dose container, no physical contact before filling
Claims 10-21	Aseptically prepared composition	Aseptic filling and sealing, 2:1 active-weight ratio, with dependent packaging, salt, dose and administration limitations

The patent does not broadly claim ceftolozane, tazobactam, or every combination of the two. It claims a specific product architecture in which the two actives are combined in a sterile unit-dose package without prior physical contact.

The claim set is directed to the stability and manufacturing problems associated with combining beta-lactam antibiotics. The separation requirement is central. A product made by premixing ceftolozane and tazobactam before filling would face a substantial noninfringement argument against claims requiring that the ingredients "were not in physical contact prior to filling."

How do claims 1 and 10 differ?

Claims 1 and 10 provide alternative infringement routes.

Claim 1 is principally a composition and packaging claim. It requires:

A sterile composition.
Ceftolozane or an acceptable salt.
Tazobactam or an acceptable salt.
A sealed unit-dose container.
A 2:1 ratio by weight based on active ceftolozane and active tazobactam.
No physical contact between the two components before filling.

Claim 10 adds a manufacturing limitation. The product must have been prepared by aseptically filling the two components into a unit-dose container and sealing it. Claim 10 does not expressly include the "no prior physical contact" limitation, but that limitation appears in dependent claim 12.

The distinction matters in litigation. A competing product could potentially avoid claim 1 by demonstrating prior physical contact, but still face claim 10 if it was aseptically co-filled at the claimed ratio. Conversely, a product made by a different filling process could face claim 1 if it satisfies the sterile composition, sealed-container and separation requirements.

What salts and dosage strengths are covered?

The patent claims the following salt and dose combinations:

Claim limitation	Scope
Ceftolozane	Ceftolozane or pharmaceutically acceptable salt
Ceftolozane salt	Specifically ceftolozane sulfate
Tazobactam	Tazobactam or pharmaceutically acceptable salt
Tazobactam salts	Tazobactam sodium or tazobactam arginine
Preferred tazobactam salt	Tazobactam sodium
Standard dose	1,000 mg ceftolozane active plus 500 mg tazobactam active
Higher dose	2,000 mg ceftolozane active plus 1,000 mg tazobactam active

The ratio is measured using active amounts, not the gross weight of the salts. A formulation containing ceftolozane sulfate and tazobactam sodium may therefore have a gross powder weight different from 2:1 while still satisfying the claimed 2:1 active ratio.

The 1,000 mg/500 mg presentation corresponds to the active amounts in the marketed 1.5 g Zerbaxa vial. The 2,000 mg/1,000 mg embodiment is also claimed, whether or not it is commercially marketed in the same presentation.

Does the patent cover Zerbaxa?

Yes, the claimed product architecture substantially tracks the approved Zerbaxa product. Zerbaxa is a sterile, injectable ceftolozane-tazobactam product supplied as a single-dose vial for reconstitution and intravenous administration. The FDA-approved vial contains ceftolozane sulfate equivalent to 1,000 mg of ceftolozane and tazobactam sodium equivalent to 500 mg of tazobactam.[2]

The following features align closely with the patent:

Zerbaxa product characteristic	Relevance to US 9,320,740
Ceftolozane-tazobactam combination	Required by independent claims
2:1 active ratio	Required by claims 1 and 10
Sterile injectable vial	Required or reinforced by claims 1, 9, 10 and 21
Ceftolozane sulfate	Expressly claimed in claims 2 and 14
Tazobactam sodium	Expressly claimed in claims 4 and 16
1,000 mg/500 mg dose	Expressly claimed in claims 5 and 17
Reconstitution before IV use	Addressed by claims 8, 9, 20 and 21
Separate lyophilization	Addressed by claims 7 and 19

The patent is therefore relevant to an ANDA applicant seeking to copy the commercial Zerbaxa vial, not merely to an applicant developing a different fixed-dose ceftolozane-tazobactam formulation.

What formulation and manufacturing features are protected?

Separate physical handling before filling

Claims 1 and 12 require that ceftolozane and tazobactam not be in physical contact before filling. This limitation may distinguish separate sterile powder streams, separate lyophilized cakes, or separately prepared components that are co-filled only at the final packaging step.

The phrase is potentially significant because it focuses on manufacturing history, not only the final container. An identical-looking final vial could have different infringement exposure depending on whether the active ingredients were premixed before filling.

Individual lyophilization

Claims 7 and 19 cover embodiments in which each active is individually lyophilized before filling. These claims narrow the independent claims but may be commercially important because lyophilization can improve stability for sterile beta-lactam products.

A competitor using a spray-dried, crystalline, granulated or non-lyophilized powder could avoid these dependent claims while remaining exposed to the broader claims.

Aseptic filling and sealing

Claims 10 and 13 focus on aseptic filling and co-filling. Claim 11 covers inert-gas blanketing before sealing. The patent therefore reaches process controls that may not be visible from the finished product.

A process claim or product-by-process limitation generally requires close analysis of claim construction and proof of the accused manufacturing process. Manufacturing records, batch documentation, regulatory filings and discovery from contract manufacturers could become important in enforcement.

Reconstitution and intravenous administration

Claims 8 and 20 cover a container with a means for injecting liquid. Claims 9 and 21 cover the composition after dissolution in a pharmaceutically acceptable carrier for intravenous administration.

These claims extend the estate beyond dry sterile powder. A product supplied as a vial intended for reconstitution, or as a prepared IV solution, may implicate different claims depending on when the claimed combination exists and how the accused product is sold.

When does US Patent 9,320,740 lose exclusivity?

The patent issued on April 26, 2016. Its relevant priority period traces to the 2012 filing period, producing a nominal patent-term endpoint in 2032 before any applicable patent-term adjustment or extension.[1]

Event	Date or period
Earliest relevant priority period	2012
Patent issue	April 26, 2016
Nominal 20-year term endpoint	2032, subject to the patent record
Zerbaxa FDA approval	December 19, 2014
QIDP-related regulatory protection	Potentially extends applicable exclusivity or patent term under statutory conditions

The exact expiration date should be taken from the USPTO patent-term calculation and the FDA Orange Book listing. Patent-term adjustment, patent-term extension and pediatric exclusivity can change the effective blocking date. A patent expiration date should not be inferred solely from the issue date.

The Qualified Infectious Disease Product designation for Zerbaxa provided an additional five years to certain applicable exclusivity periods or patent terms under the statutory framework. That regulatory benefit does not independently create a patent and does not automatically apply to every patent in the portfolio.[2][3]

What is the Orange Book status of US 9,320,740?

Zerbaxa is approved under NDA 206829. The FDA Orange Book is the controlling source for current patent-listing status, expiration dates and any applicable exclusivity information.[3]

The commercial significance of US 9,320,740 depends on whether it remains listed for the NDA and which claims the FDA accepted as covering the approved drug. A listed formulation or packaging patent can require an ANDA applicant to submit a Paragraph IV certification or a section viii statement, depending on the scope of the listed patent and the proposed labeling.

The patent is more likely to be relevant to a product-specific ANDA than to a 505(b)(2) application that uses a materially different presentation, manufacturing process or dosage form. A section viii strategy would be difficult if the approved labeling requires the patented intravenous vial and reconstitution configuration.

Which companies could challenge the patent through Paragraph IV?

An ANDA applicant seeking approval for a generic ceftolozane-tazobactam product could use one of four general positions:

Strategy	Patent exposure
Paragraph III certification	Approval deferred until patent expiration
Paragraph IV certification	Applicant alleges invalidity, unenforceability or noninfringement
Section viii statement	Applicant omits patented method-of-use information, where legally available
Non-infringing formulation	Applicant changes ratio, packaging, filling sequence or dosage form

The most credible technical noninfringement routes would involve:

A ratio other than 2:1 by active weight.
Premixing the active ingredients before filling.
A multi-dose rather than unit-dose container.
A formulation that is not sterile at the claimed packaged stage.
A non-injectable dosage form.
A manufacturing process that does not use aseptic co-filling.
A container without the claimed reconstitution structure.

A generic company cannot avoid infringement merely by changing excipients if all independent claim limitations remain present. The patent contains no narrow excipient limitation in claims 1 or 10.

What patent litigation affects Zerbaxa and US 9,320,740?

Patent litigation risk is concentrated in ANDA litigation involving Merck's Zerbaxa rights and related ceftolozane-tazobactam patents. The relevant defendants would be generic applicants that file Paragraph IV certifications against Orange Book-listed patents.

The existence of an ANDA filing does not establish infringement. A claim-by-claim analysis would examine:

The proposed generic's active ratio.
Whether the ingredients are separately handled before filling.
The type of vial or container.
Whether the product is individually lyophilized.
The aseptic filling sequence.
The proposed labeling and IV reconstitution instructions.
The identity and quantity of the active salts.

A settlement could provide a licensed launch date before patent expiration, but the patent claims supplied do not establish the terms of any settlement agreement. Settlement terms, if any, must be assessed from the relevant district court docket, FTC disclosures and FDA approval history.

How strong is the patent estate for ceftolozane-tazobactam?

The estate is strongest against a copy of the approved Zerbaxa vial. Its strength declines as a competitor changes the product architecture.

Risk category	Assessment
Exact 1,000/500 mg sterile vial	High
Same salts and separate lyophilized components	High
Same ratio but different sterile container	Moderate to high
Same actives with premixing before filling	Reduced for separation claims
Different active ratio	Reduced substantially
Non-injectable product	Low under claims 9 and 21, subject to independent claims
Different manufacturing process	Reduced for process-limited claims
Reformulated hospital presentation	Fact-dependent

The claims have meaningful commercial breadth because the independent claims do not require particular excipients, lyophilization, inert gas or a specific vial design. At the same time, the claims are vulnerable to design-around because they require a specific active ratio, unit-dose packaging and, for claims 1-9, a particular separation history.

What generic launch scenarios exist?

Launch after patent expiry

This is the lowest-litigation scenario. The applicant accepts the patent and times approval or commercial launch after the effective patent and regulatory exclusivity dates.

Paragraph IV challenge

The applicant seeks earlier approval and argues that the patent is invalid or not infringed. Likely validity issues could include written description, enablement, obviousness, anticipation and the legal treatment of the "not in physical contact prior to filling" limitation.

Non-infringing 505(b)(2) product

A sponsor could pursue a materially different presentation, such as a different ratio, container configuration or preparation method. Regulatory comparability and stability requirements would still be substantial.

Hospital-compounded or alternative presentation

A product supplied as separate components rather than a patented co-filled unit-dose container could reduce exposure to the composition claims. The regulatory pathway and clinical labeling would differ from a direct generic copy.

What geographic coverage does the patent provide?

US Patent 9,320,740 provides rights only in the United States. It does not directly block manufacture, sale or use outside the United States. Foreign counterparts must be assessed separately by jurisdiction, including:

Filing and grant status.
National-phase claim scope.
Patent-term adjustments.
Supplementary protection certificates.
Local Orange Book equivalents.
Pending opposition or invalidity proceedings.

A manufacturer may still face US infringement risk if it makes a product abroad for importation into the United States under 35 U.S.C. § 271(a) or § 271(g), depending on the conduct and the asserted claims.

Key Takeaways

US 9,320,740 is a product, packaging and manufacturing patent directed to sterile ceftolozane-tazobactam combinations.
The commercial center of gravity is the 1,000 mg ceftolozane/500 mg tazobactam sterile vial.
The independent claims require a 2:1 active-weight ratio and a sealed unit-dose container.
Claims 1 and 12 make prior physical separation a material limitation.
Claims 7 and 19 protect individually lyophilized components.
Claims 10 and 13 add aseptic filling and co-filling process limitations.
Claims 9 and 21 cover IV compositions after dissolution in a pharmaceutically acceptable carrier.
A generic copy of the Zerbaxa vial faces materially greater risk than a product using a different ratio, container, filling sequence or dosage form.
The nominal term extends into 2032, subject to USPTO patent-term calculations and any applicable statutory extensions.
FDA Orange Book status, current patent term and any Paragraph IV litigation should control launch-date analysis.

FAQs

Can a generic use the same ceftolozane-tazobactam ratio in a different vial?

Possibly. A different vial may avoid some packaging limitations, but it would not automatically avoid claims 1 or 10 if it remains a sterile, sealed unit-dose product prepared with the claimed separation and filling characteristics.

Does changing tazobactam sodium to tazobactam arginine avoid the patent?

Not necessarily. Claims 3 and 15 expressly include tazobactam arginine. A different pharmaceutically acceptable salt would require separate claim-construction and equivalence analysis.

Does a 1,500 mg total powder weight avoid the 2:1 limitation?

No. The ratio is based on active ceftolozane and active tazobactam, not the total gross weight of the salts or excipients.

Can a competitor avoid infringement by supplying ceftolozane and tazobactam in separate vials?

A genuinely separate-vial product may avoid the unit-dose co-filled container claims. The result depends on whether the accused product is treated as a claimed unit dosage form and whether the relevant claims are infringed by the marketed presentation.

Are biosimilars relevant to ceftolozane-tazobactam?

No. Ceftolozane and tazobactam are small-molecule antibacterial active ingredients. The principal competitive pathway is an ANDA or, for a materially different product, a 505(b)(2) application, rather than a biosimilar application under the Public Health Service Act.

References

United States Patent and Trademark Office. (2016). US Patent No. 9,320,740, pharmaceutical compositions comprising ceftolozane and tazobactam.
U.S. Food and Drug Administration. (2024). Zerbaxa (ceftolozane and tazobactam) prescribing information. Merck Sharp & Dohme LLC.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Congress. (2012). Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144, provisions concerning qualified infectious disease products.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	9,320,740*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014227660	⤷ Start Trial
Australia	2015200599	⤷ Start Trial
Brazil	112015023523	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,320,740

Which drugs does patent 9,320,740 protect, and when does it expire?

Summary for Patent: 9,320,740